Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.86 Million USD | -13.33% |
| 2022 | 12.53 Million USD | 7.35% |
| 2021 | 11.68 Million USD | 36.77% |
| 2020 | 8.54 Million USD | 1081.19% |
| 2019 | 723 Thousand USD | 82.12% |
| 2018 | 397 Thousand USD | -73.08% |
| 2017 | 1.47 Million USD | 4.98% |
| 2016 | 1.4 Million USD | -49.5% |
| 2015 | 2.78 Million USD | -39.31% |
| 2014 | 4.58 Million USD | 10.7% |
| 2013 | 4.14 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.77 Million USD | 13.65% |
| 2024 Q1 | 2.43 Million USD | 11.12% |
| 2023 Q1 | 3.08 Million USD | 19.5% |
| 2023 Q3 | 2.66 Million USD | -9.08% |
| 2023 Q2 | 2.92 Million USD | -5.0% |
| 2023 FY | 10.86 Million USD | -13.33% |
| 2023 Q4 | 2.19 Million USD | -17.54% |
| 2022 Q1 | 3.34 Million USD | -1.76% |
| 2022 Q4 | 2.57 Million USD | -19.48% |
| 2022 Q3 | 3.2 Million USD | -6.13% |
| 2022 FY | 12.53 Million USD | 7.35% |
| 2022 Q2 | 3.41 Million USD | 2.03% |
| 2021 Q1 | 2.65 Million USD | -23.36% |
| 2021 Q4 | 3.4 Million USD | 30.37% |
| 2021 Q3 | 2.61 Million USD | -13.28% |
| 2021 FY | 11.68 Million USD | 36.77% |
| 2021 Q2 | 3.01 Million USD | 13.45% |
| 2020 FY | 8.54 Million USD | 1081.19% |
| 2020 Q3 | 2.66 Million USD | 0.0% |
| 2020 Q4 | 3.46 Million USD | 29.89% |
| 2019 FY | 723 Thousand USD | 82.12% |
| 2019 Q1 | 812 Thousand USD | 112.57% |
| 2019 Q2 | 605 Thousand USD | -25.49% |
| 2018 Q2 | 405.99 Thousand USD | -26.58% |
| 2018 Q1 | 552.99 Thousand USD | 2.22% |
| 2018 Q3 | 633 Thousand USD | 55.91% |
| 2018 FY | 397 Thousand USD | -73.08% |
| 2018 Q4 | 382 Thousand USD | -39.65% |
| 2017 Q1 | 380 Thousand USD | 17.28% |
| 2017 FY | 1.47 Million USD | 4.98% |
| 2017 Q3 | 544.99 Thousand USD | 154.67% |
| 2017 Q2 | 214 Thousand USD | -43.68% |
| 2017 Q4 | 540.99 Thousand USD | -0.73% |
| 2016 Q1 | 382 Thousand USD | -57.27% |
| 2016 Q2 | 377 Thousand USD | -1.31% |
| 2016 Q4 | 323.99 Thousand USD | -35.33% |
| 2016 FY | 1.4 Million USD | -49.5% |
| 2016 Q3 | 501 Thousand USD | 32.89% |
| 2015 Q3 | 416 Thousand USD | -50.18% |
| 2015 Q4 | 894 Thousand USD | 114.9% |
| 2015 Q1 | 822 Thousand USD | -11.61% |
| 2015 Q2 | 835 Thousand USD | 1.58% |
| 2015 FY | 2.78 Million USD | -39.31% |
| 2014 Q1 | 1.02 Million USD | 42.34% |
| 2014 Q2 | 1.39 Million USD | 36.4% |
| 2014 Q4 | 930 Thousand USD | -24.88% |
| 2014 Q3 | 1.23 Million USD | -11.19% |
| 2014 FY | 4.58 Million USD | 10.7% |
| 2013 Q2 | 1.02 Million USD | -14.0% |
| 2013 Q1 | 1.19 Million USD | 0.0% |
| 2013 Q4 | 718 Thousand USD | -40.32% |
| 2013 FY | 4.14 Million USD | 0.0% |
| 2013 Q3 | 1.2 Million USD | 17.25% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -713.745% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -115.528% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 63.229% |
| Nascent Biotech, Inc. | 2.22 Million USD | -387.336% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1536.596% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 70.831% |
| Qrons Inc. | 643.67 Thousand USD | -1588.269% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2689.514% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 81.081% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2515.535% |
| Skye Bioscience, Inc. | 13.54 Million USD | 19.786% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 87.478% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -120.968% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -4052.052% |
| SQZ Biotechnologies Company | 85.61 Million USD | 87.308% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -272.638% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -623.551% |
| Mesoblast Limited | 5.9 Million USD | -84.124% |
| Marizyme, Inc. | 19.23 Million USD | 43.518% |
| Genus plc | 147.7 Million USD | 92.643% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -23.781% |
| Pharming Group N.V. | 225.49 Million USD | 95.181% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -430.433% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -710.036% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -30.315% |
| ContraFect Corporation | 56.88 Million USD | 80.898% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -146.491% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -634.876% |
| IMV Inc. | 37.7 Million USD | 71.182% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -289.448% |
| MultiCell Technologies, Inc. | 567.42 USD | -1915059.846% |
| ONE Bio Corp. | 6.44 Million USD | -68.64% |
| Accustem Sciences Inc. | 3.74 Million USD | -190.064% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 87.356% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1942.815% |
| Q BioMed Inc. | 3.43 Million USD | -216.211% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 56.031% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -313.584% |
| Biomind Labs Inc. | 994.18 Thousand USD | -993.059% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 89.06% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -517.556% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -61.759% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -482.878% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 43568.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 32.125% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -492.176% |
| GB Sciences, Inc. | 1.42 Million USD | -665.007% |
| Alpha Cognition Inc. | 9.7 Million USD | -11.966% |
| HST Global, Inc. | 140.9 Thousand USD | -7612.179% |
| CSL Limited | 3.44 Billion USD | 99.685% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -866.033% |
| Halberd Corporation | 74.84 Thousand USD | -14419.922% |
| Enzolytics Inc. | 2.17 Million USD | -398.599% |
| Agentix Corp. | 1.37 Million USD | -692.196% |
| Resverlogix Corp. | 12.71 Million USD | 14.514% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -197.668% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.291% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -940.9% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -351.863% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -588.066% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -219.15% |
| AVAX Technologies, Inc. | 7.31 Million USD | -48.654% |
| Zenith Capital Corp. | 8.94 Million USD | -21.514% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.683% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -62278.738% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -342.591% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -6236.111% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -465.723% |
| Kadimastem Ltd | 2.41 Million USD | -350.892% |
| Helix BioMedix, Inc. | 1.97 Million USD | -451.055% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 52.7% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -5887.823% |
| LadRx Corporation | 3.81 Million USD | -185.089% |
| Cell Source, Inc. | 4.32 Million USD | -151.24% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1076.706% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1076.706% |
| NovAccess Global Inc. | 2.46 Million USD | -340.537% |
| Affymax, Inc. | 39.38 Million USD | 72.409% |
| Itoco Inc. | 919.14 Thousand USD | -1082.297% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -156.393% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -871.135% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1859.621% |
| CytoDyn Inc. | 18.05 Million USD | 39.822% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -43076.129% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4837.795% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -665.394% |
| SYBLEU INC | 160.87 Thousand USD | -6654.892% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -498.298% |
| International Stem Cell Corporation | 5.27 Million USD | -106.166% |
| Bioxytran, Inc. | 3.82 Million USD | -184.465% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -20543.213% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -53318.866% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 70.035% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -571.632% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1376.826% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -249.309% |
| Neutra Corp. | 243.82 Thousand USD | -4356.958% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 37.75% |
| PureTech Health plc | 144.59 Million USD | 92.485% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 46.964% |
| IXICO plc | 4.7 Million USD | -130.869% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -23.531% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 90.771% |
| CSL Limited | 3.89 Billion USD | 99.721% |
| Cellectis S.A. | 97.32 Million USD | 88.834% |